Biosyent (RX) AI Stock Analysis

• Market Cap: C$129.67M
• Dividend Yield: 1.67%
• Average Volume (3M): 2.35K
• Price to Earnings (P/E): 16.5
• Beta (1Y): 0.31
• Revenue Growth: 16.55%
• EPS Growth: 14.70%
• Country: CA
• Employees: 60
• Sector: Healthcare
• Sector Strength: 52
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 11,474,931
• 10 Day Avg. Volume: 2,161
• 30 Day Avg. Volume: 2,354
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$12.75
• Price Target Upside: 12.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: C$13.00 ▲(14.54% Upside)

Biosyent's overall stock score reflects its strong financial performance and positive earnings call, which highlight robust revenue growth and profitability. While technical analysis indicates a neutral trend, and valuation is fair, the company's strategic initiatives and solid financial health position it well for future growth.

Positive Factors

Asset Acquisition

BioSyent announced the acquisition of the global rights to Tibella (Tibolone) for EUR 2.8M (~$4.24M CAD) from Mithra Pharmaceuticals SA and its subsidiary Novalon SA.

Financial Performance

BioSyent reported results that exceeded estimates.

Negative Factors

Asset Quality

No physical assets such as production plants or employees were acquired.

Revenue

The topline came in a bit below estimates.

Biosyent Business Overview & Revenue Model

Company Description

Biosyent (RX) is a Canadian pharmaceutical company focused on the development, licensing, and marketing of innovative healthcare products. Operating primarily in the prescription and over-the-counter medication sectors, Biosyent aims to enhance the well-being of patients by providing effective solutions. The company specializes in niche therapeutic areas, offering products that cater to specific medical needs and improve patient outcomes.

How the Company Makes Money

Biosyent generates revenue through the sale of its pharmaceutical products. The company's revenue model primarily relies on the licensing and distribution agreements it establishes with global pharmaceutical manufacturers. These partnerships allow Biosyent to market and sell third-party developed products in Canada and selected international markets. The company's earnings are driven by the sales of both prescription medications and over-the-counter products, which are distributed through a network of healthcare providers, pharmacies, and distributors. Additionally, Biosyent may engage in strategic partnerships or acquisitions to expand its product portfolio and market reach, further contributing to its revenue streams.

Biosyent Financial Statement Overview

Summary

Biosyent demonstrates strong profitability with high gross and net profit margins and impressive revenue growth. The balance sheet is solid with low debt and high equity, reflecting financial stability. However, cash flow management shows room for improvement, with a significant decrease in free cash flow.

Income Statement

Biosyent demonstrates strong profitability with consistently high gross and net profit margins. The gross profit margin for TTM (Trailing-Twelve-Months) is 78.5%, and the net profit margin is 20.4%, indicating effective cost management and solid profitability. Revenue growth is also impressive, with a TTM growth rate of 9.2% compared to the previous year. The EBIT and EBITDA margins are healthy, at 25.2% and 29.5% respectively, showing robust operational efficiency.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.03, indicating low leverage and financial stability. The return on equity (ROE) is 21.7%, reflecting effective use of equity to generate profits. The equity ratio is high at 84.2%, underscoring a solid equity base. Overall, the company's financial position is stable with ample equity and minimal debt, although the slight decrease in cash reserves is noteworthy.

Cash Flow

Biosyent's cash flow performance is solid with a positive free cash flow, although the free cash flow has decreased by 45.6% in the TTM period. The operating cash flow to net income ratio of 0.89 indicates good cash conversion, while the free cash flow to net income ratio of 0.28 suggests some room for improvement in cash flow management. Despite the decrease in free cash flow, overall cash flow stability is maintained.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.03M	31.59M	27.93M	28.62M	22.33M
Gross Profit	27.86M	25.60M	22.86M	22.64M	17.42M
EBITDA	10.43M	9.06M	7.96M	8.92M	5.84M
Net Income	7.27M	6.46M	5.46M	6.28M	3.80M
Balance Sheet
Total Assets	41.36M	41.53M	40.49M	37.17M	33.57M
Cash, Cash Equivalents and Short-Term Investments	15.94M	26.19M	28.70M	28.21M	25.58M
Total Debt	1.04M	1.22M	1.40M	1.56M	1.71M
Total Liabilities	6.36M	6.77M	7.12M	5.61M	6.78M
Stockholders Equity	35.00M	34.76M	33.36M	31.55M	26.80M
Cash Flow
Free Cash Flow	3.99M	4.88M	4.43M	4.58M	6.72M
Operating Cash Flow	8.66M	5.05M	4.95M	4.67M	6.89M
Investing Cash Flow	3.29M	883.85K	-10.79M	-4.84M	3.39M
Financing Cash Flow	-7.83M	-5.78M	-4.37M	-2.08M	-3.37M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.35
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Positive. The current price of 11.35 is below the 20-day moving average (MA) of 11.43, below the 50-day MA of 11.60, and above the 200-day MA of 11.19, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.76 is Neutral, neither overbought nor oversold. The STOCH value of 48.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	78 Outperform	C$129.67M	16.51	22.17%	1.67%	16.55%	14.70%
MDP	67 Neutral	C$91.94M	68.37	1.88%	―	0.03%	-17.30%
TH	61 Neutral	$206.45M	―		―	5.24%	-7.99%
HLS	53 Neutral	C$161.99M	―	-20.58%	―	-1.42%	35.15%
CTX	52 Neutral	C$8.88M	―	-8.12%	―	20.33%	53.93%
Sector *	51 Neutral	$7.76B	-0.12	-40.59%	2.21%	22.68%	-1.42%
AQS	21 Underperform	C$663.17K	―	43.02%	―	252.34%	24.88%

Biosyent Corporate Events

BioSyent to Announce Q2 and H1 2025 Financial Results

BioSyent Inc. has announced that it will release its financial results for the second quarter and first half of 2025 on August 21, 2025, after market hours. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent Declares Consistent Second Quarter 2025 Dividend

BioSyent Inc. has announced a quarterly dividend of $0.05 per common share for the second quarter of 2025, payable on June 13, 2025, to shareholders of record as of May 30, 2025. This dividend is consistent with the first quarter’s dividend and is classified as an ‘eligible dividend’ for Canadian tax purposes. The announcement underscores BioSyent’s ongoing commitment to providing shareholder value and reflects its stable financial performance.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent Reports Robust Q1 2025 Financial Performance and Strategic Board Appointment

BioSyent Inc. reported strong financial results for the first quarter of 2025, with total company sales increasing by 42% compared to the first quarter of 2024. The company saw significant growth in its Canadian and international pharmaceutical sales, as well as its legacy business. Notably, the FeraMAX Pd product line continued to lead in the Canadian market for iron health, and the Tibelia product showed substantial growth following the acquisition of global product rights. Despite uncertainties in international trade, BioSyent remains focused on long-term growth and portfolio diversification. Additionally, the company announced the election of Mr. Prakash Gowd to its Board of Directors, succeeding Mr. Larry Andrews.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.